V
Vesna Bjelic-Radisic
Researcher at Medical University of Graz
Publications - 136
Citations - 4410
Vesna Bjelic-Radisic is an academic researcher from Medical University of Graz. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 26, co-authored 117 publications receiving 3577 citations. Previous affiliations of Vesna Bjelic-Radisic include Witten/Herdecke University & University of Graz.
Papers
More filters
Journal ArticleDOI
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant,Brigitte Mlineritsch,Walter Schippinger,G. Luschin-Ebengreuth,Sabine Pöstlberger,Christian Menzel,Raimund Jakesz,Michael Seifert,Michael Hubalek,Vesna Bjelic-Radisic,Hellmut Samonigg,C. Tausch,Holger Eidtmann,Guenther G. Steger,Werner Kwasny,Peter Dubsky,M. Fridrik,Florian Fitzal,Michael Stierer,Ernst Rücklinger,Richard Greil +20 more
TL;DR: The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer.
Journal ArticleDOI
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo- controlled trial
Michael Gnant,Georg Pfeiler,Peter Dubsky,Michael Hubalek,Richard Greil,Raimund Jakesz,Viktor Wette,Marija Balic,Ferdinand Haslbauer,Elisabeth Melbinger,Vesna Bjelic-Radisic,Silvia Artner-Matuschek,Florian Fitzal,Christian Marth,Paul Sevelda,Brigitte Mlineritsch,Günther G. Steger,Diether Manfreda,Ruth Exner,Daniel Egle,Jonas Bergh,Franz Kainberger,Susan Talbot,Douglas Warner,Christian Fesl,Christian F. Singer +25 more
TL;DR: Adjuvant denosumab 60 mg twice per year reduces the risk of clinical fractures in postmenopausal women with breast cancer receiving aromatase inhibitors, and can be administered without added toxicity.
Journal ArticleDOI
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant,Brigitte Mlineritsch,G. Luschin-Ebengreuth,Franz Kainberger,Helmut Kässmann,Jutta Claudia Piswanger-Sölkner,Michael Seifert,Ferdinand Ploner,Christian Menzel,Peter Dubsky,Florian Fitzal,Vesna Bjelic-Radisic,Günther G. Steger,Richard Greil,Christian Marth,Ernst Kubista,Hellmut Samonigg,Peter Wohlmuth,Martina Mittlböck,Raimund Jakesz +19 more
TL;DR: A randomised, open-label, phase III, 4-arm trial comparing tamoxifen and goserelin versus anastrozole and zoledronic acid for preventing bone loss associated with adjuvant endocrine therapy and reports on long-term findings of bone-mineral density (BMD) during 3 years of treatment and 2 years after completing adjuant treatment with or without zoledronics acid.
Journal ArticleDOI
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Michael Gnant,Brigitte Mlineritsch,Herbert Stoeger,G. Luschin-Ebengreuth,Michael Knauer,Martin Moik,Raimund Jakesz,Michael Seifert,Susanne Taucher,Vesna Bjelic-Radisic,Marija Balic,Holger Eidtmann,Wolfgang Eiermann,Günther G. Steger,Werner Kwasny,Peter Dubsky,U Selim,Florian Fitzal,Gerhard Hochreiner,Viktor Wette,Paul Sevelda,Ferdinand Ploner,Rupert Bartsch,Christian Fesl,Richard Greil +24 more
TL;DR: The final results from ABCSG 12 suggest that twice-yearly ZOL enhances the efficacy of adjuvant endocrine treatment, and this benefit is maintained long-term.
Journal ArticleDOI
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
Georg Pfeiler,Robert Königsberg,Christian Fesl,Brigitte Mlineritsch,Herbert Stoeger,Christian F. Singer,Sabine Pöstlberger,Guenther G. Steger,Michael Seifert,Peter Dubsky,Susanne Taucher,Hellmut Samonigg,Vesna Bjelic-Radisic,Richard Greil,Christian Marth,Michael Gnant +15 more
TL;DR: BMI significantly impacts on the efficacy of anastrozole plus goserelin in premenopausal patients with breast cancer, probably through influencing aromatase availability and/or ovarian suppression by gose Relin.